All In Biotech

Drug Trial Radar · NCT07697846

A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adults

Phase 1, Single-Center, Randomized, Double-Blind, Parallel-Group Placebo-Controlled(Concentration)-QTc(C-QTc)Study to Evaluate the Impact of ZT002 Injection on QTc Interval in Chinese Overweight and Obese Subjects

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 15, 2026

Primary completion

Jan 13, 2027

Study completion Mar 24, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is designed to investigate the effect of treatment with Zovaglutide (ZT002 Injection) on the corrected cardiac QT interval relative to a placebo control in healthy participants.

Conditions

  • Overweight, Obesity

Interventions

  • ZT002 injectionDrug

    Subjects will receive subcutaneous injections of Zovaglutide (ZT002 Injection) once every two weeks.

  • ZT002 injection matching placeboDrug

    Subjects will receive subcutaneous injections of ZT002 injection matching placebo once every two weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change to baseline- and placebo-corrected QTc interval (ΔΔQTc)Time frame: Up to Day 141

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing GoBroad Hospital

    Beijing, China, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.